Stockscreener 앱 받기
1.23
1.60%
-0.02
전일 마감가:
$1.25
열려 있는:
$1.25
하루 거래량:
349.31K
Relative Volume:
0.13
시가총액:
$3.16M
수익:
$212.10K
순이익/손실:
$-40.19M
주가수익비율:
-0.000231
EPS:
-5313.2836
순현금흐름:
$-13.92M
1주 성능:
-21.15%
1개월 성능:
-19.61%
6개월 성능:
-97.63%
1년 성능:
-99.99%
1일 변동 폭
$1.1903
$1.26
1주일 범위
$1.11
$1.53
52주 변동 폭
$1.11
$27,200.00
애디텍스트 Stock (ADTX) Company Profile
명칭
Aditxt Inc
전화
909-488-0844
주소
737 N. FIFTH STREET, SUITE 200, RICHMOND
ADTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADTX
Aditxt Inc
|
1.23 | 3.16M | 212.10K | -40.19M | -13.92M | -5,313.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
애디텍스트 주식(ADTX)의 최신 뉴스
Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting - Benzinga
Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board - citybiz
Aditxt Inc. Strengthens Board with Appointment of Evofem CEO Saundra Pelletier - citybuzz -
Aditxt names Evofem CEO to its board, eyes women’s health market By Investing.com - Investing.com South Africa
Aditxt names Evofem CEO to its board, eyes women’s health market - Investing.com India
Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board Of Directors - MarketScreener
Aditxt (ADTX) Welcomes Saundra Pelletier to Its Board | ADTX Stock News - GuruFocus
Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors | ADTX Stock News - GuruFocus
Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board of Directors - Business Wire
Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, - GuruFocus
Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO Of Adimune, And Chris Mitton, President Of Pearsanta, Will Join Aditxt Weekly Update On June 6 - MarketScreener
Saundra Pelletier, Evofem Biosciences’ CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6 - Bluefield Daily Telegraph
Healthcare Innovation Leaders From Evofem, Adimune, and Pearsanta Preview New Developments at Aditxt Update - Stock Titan
Aditxt (NASDAQ:ADTX) Shares Down 8.1% – Time to Sell? - Defense World
Aditxt Highlights Strategic Partnership with Evofem Biosciences - TipRanks
ADTX stock plunges to 52-week low, touches $1.5 amid steep decline By Investing.com - Investing.com South Africa
ADTX stock plunges to 52-week low, touches $1.5 amid steep decline - Investing.com Nigeria
Stocks In Play: Appili Therapeutics Inc. By Baystreet.ca - Investing.com Canada
Appili Therapeutics Inc. - Baystreet.ca
Appili Therapeutics Ends Agreement with Aditxt, Secures Loan Extensions - TipRanks
Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc. - The Manila Times
Options Volatility and Implied Earnings Moves Today, May 29, 2025 - The Globe and Mail
Aditxt secures $233K loan from CEO Albanna - Investing.com Australia
Aditxt secures $233K loan from CEO Albanna By Investing.com - Investing.com South Africa
Aditxt Issues Unsecured Promissory Note in Strategic Move - TipRanks
Aditxt (ADTX) Cancels Acquisition Agreement with Appili Therapeu - GuruFocus
Aditxt Discusses Strategic Focus and Growth Plans - TipRanks
Aditxt to Scrap Merger Deal With Appili Therapeutics - marketscreener.com
Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics | ADTX Stock News - GuruFocus
Aditxt Announces Termination Of Arrangement Agreement With Appili Therapeutics - marketscreener.com
Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc. - The Manila Times
Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics - Eagle-Tribune
Aditxt, Inc. SEC 10-Q Report - TradingView
Aditxt (NASDAQ:ADTX) Shares Down 5.5% – What’s Next? - Defense World
Aditxt Highlights Progress of ADI-100TM in Autoimmune Treatment - TipRanks
Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™ - Quantisnow
Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, - GuruFocus
Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department - GuruFocus
Aditxt secures $256K through senior note sales By Investing.com - Investing.com Nigeria
Aditxt secures $256K through senior note sales - Investing.com
Aditxt’s Subsidiary Pearsanta Gets IRB Approval - TipRanks
애디텍스트 (ADTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
애디텍스트 주식 (ADTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| HRT FINANCIAL LP | 10% Owner |
Oct 16 '24 |
Sale |
1.17 |
25,534 |
29,875 |
0 |
0.68%
0.50%
자본화:
|
볼륨(24시간):